Haydar Frangoul, MD, MS

Medical director, pediatric hematology/oncology, Sarah Cannon Pediatric Transplant and Cellular Therapy Program, TriStar Centennial, and investigator, Sarah Cannon Research Institute

Articles by Haydar Frangoul, MD, MS

Counseling Patients On Exa-cel Gene Therapy Journey, With Haydar Frangoul, MD, MS

ByHaydar Frangoul, MD, MS

July 21st 2026

Exa-cel requires careful counseling on treatment timelines, chemotherapy conditioning, fertility risks, and the gene therapy journey.

Exa-Cel Approval Expands to Children as Young as 2 With Haydar Frangoul, MD

FDA Expands Exa-Cel (Casgevy) Approval, Bringing Gene Therapy to Younger Children

ByHaydar Frangoul, MD, MS

July 20th 2026

Haydar Frangoul, MD, discusses how the expanded indication may allow earlier conversations about curative therapy and intervention before irreversible complications develop.

Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy

ByVictoria Johnson,Haydar Frangoul, MD, MS

December 8th 2024

Frangoul discussed highlights from the latest data update from the CLIMB SCD-121 trial of Casgevy.

Haydar Frangoul, MD, MS

Articles by Haydar Frangoul, MD, MS

Counseling Patients On Exa-cel Gene Therapy Journey, With Haydar Frangoul, MD, MS

FDA Expands Exa-Cel (Casgevy) Approval, Bringing Gene Therapy to Younger Children

Haydar Frangoul, MD: Preventing VOCs in People With Sickle Cell Disease With Exa-Cel Gene Editing Therapy

Latest Updated Articles

Trending on HCPLive

Bringing Bronchiectasis Guidelines Into Everyday Practice

The Future of Bronchiectasis Care: Precision Medicine Ahead

Does Artificial Intelligence Worsen Health Care Disparities?

Inhaled Antibiotics for Pseudomonas in Bronchiectasis

Sequencing Therapies for Bronchiectasis: A Practical Approach